These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 15661271

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
    Cilloni D, Messa F, Gottardi E, Fava M, Arruga F, Defilippi I, Carturan S, Messa E, Morotti A, Giugliano E, Rege-Cambrin G, Alberti D, Baccarani M, Saglio G.
    Cancer; 2004 Sep 01; 101(5):979-88. PubMed ID: 15329907
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 01; 26(1):1-5. PubMed ID: 15946498
    [Abstract] [Full Text] [Related]

  • 5. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu, Turkina AG, Misiurin AV, Aksenova EV, Domracheva EV, Zakharova AV, Khoroshko ND.
    Ter Arkh; 2007 Jan 01; 79(4):49-53. PubMed ID: 17564019
    [Abstract] [Full Text] [Related]

  • 6. Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases.
    Miglino M, Varaldo R, Colombo N, Grasso R, Clavio M, Garuti A, Aquino S, Albarello A, Sessarego M, Gobbi M.
    J Exp Clin Cancer Res; 2006 Sep 01; 25(3):321-4. PubMed ID: 17167971
    [Abstract] [Full Text] [Related]

  • 7. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2003 Sep 01; 17(9):1687-94. PubMed ID: 12970765
    [Abstract] [Full Text] [Related]

  • 8. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, Lipton JH.
    Cancer; 2008 Aug 15; 113(4):772-81. PubMed ID: 18543309
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A, Prasad K.
    J Assoc Physicians India; 2007 Feb 15; 55():109-13. PubMed ID: 17571739
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
    Beránek M, Voglová J, Sýkorová A, Belada D, Bláha M.
    Cas Lek Cesk; 2006 Feb 15; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
    [Abstract] [Full Text] [Related]

  • 13. Cytogenetic and molecular mechanisms of resistance to imatinib.
    Hochhaus A.
    Semin Hematol; 2003 Apr 15; 40(2 Suppl 2):69-79. PubMed ID: 12783379
    [Abstract] [Full Text] [Related]

  • 14. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
    Kim YJ, Kim DW, Lee S, Min CK, Goh HG, Kim SH, Lee JY, Kim YL, Kim HJ, Kim HJ, Lee JW, Kim TG, Min WS, Kim CC.
    Biol Blood Marrow Transplant; 2004 Oct 15; 10(10):718-25. PubMed ID: 15389438
    [Abstract] [Full Text] [Related]

  • 15. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.
    Clin Cancer Res; 2005 May 01; 11(9):3425-32. PubMed ID: 15867244
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
    Yagasaki F, Niwa T, Abe A, Ishikawa M, Kato C, Ogura K, Sasaki H, Kyo T, Jinnai I, Bessyo M, Miyamura K.
    Rinsho Ketsueki; 2009 Jun 01; 50(6):481-7. PubMed ID: 19571508
    [Abstract] [Full Text] [Related]

  • 18. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.
    Moravcová J, Zmeková V, Klamová H, Voglová J, Faber E, Michalová K, Rabasová J, Jarosová M.
    Leuk Res; 2004 Apr 01; 28(4):415-9. PubMed ID: 15109543
    [Abstract] [Full Text] [Related]

  • 19. Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response.
    Cariani E, Capucci M, Micheletti M, Spalenza F, Zanella I, Albertini A, Rossi G.
    Ann Hematol; 2003 Jun 01; 82(6):333-5. PubMed ID: 12734675
    [Abstract] [Full Text] [Related]

  • 20. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
    Qin YZ, Li JL, Zhu HH, Ruan GR, Li LD, Zhang Y, Xu LP, Liu DH, Liu YR, Huang XJ, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug 01; 27(8):511-4. PubMed ID: 17172121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.